“GSK Acquires Global Rights to China-Developed Multiple Myeloma Drug in Major Pipeline Expa” — what this page in the network covers. GlaxoSmithKline (GSK) has secured global rights to a promising multiple myeloma therapy developed by Shanghai-based biotech company Hengrui Medicine, marking a strategic pivot in GSK’s oncology portfolio. The deal, finalized in early 2024, grants GSK exclusive commercialization and development rights outside of China, with an undisclosed upfront payment and potential milestone payments exceeding $500 million. The drug, known as SHR-A1901, is a next-generation BCL-2 inhibitor that has shown encouraging Phase 2 results in patients with relapsed or refractory multiple myeloma, a rare but aggressive blood cancer affecting over 30,000 Americans annually.
This acquisition underscores GSK’s broader effort to strengthen its pipeline amid declining internal innovation and increased competition from Chinese biotech firms. The move also highlights the growing influence of Asia in global pharmaceutical R&D, particularly in oncology. This listing links straight to the original page, where the content is available in full.